CSIMarket
 
Pacific Biosciences Of California Inc   (PACB)
Other Ticker:  
 
 
Price: $5.1900 $-0.34 -6.148%
Day's High: $5.54 Week Perf: -0.76 %
Day's Low: $ 5.18 30 Day Perf: -20.28 %
Volume (M): 7,256 52 Wk High: $ 14.55
Volume (M$): $ 37,660 52 Wk Avg: $9.81
Open: $5.50 52 Wk Low: $4.97



 Market Capitalization (Millions $) 1,316
 Shares Outstanding (Millions) 254
 Employees 500
 Revenues (TTM) (Millions $) 200
 Net Income (TTM) (Millions $) -307
 Cash Flow (TTM) (Millions $) -146
 Capital Exp. (TTM) (Millions $) 9

Pacific Biosciences Of California Inc
Pacific Biosciences of California Inc.
(also known as PacBio) is an American biotechnology company founded in 2004 by Stephen Turner and Jonas Korlach.
The company is headquartered in Menlo Park, California, and specializes in advanced DNA sequencing technology.
PacBio aims to revolutionize the field of genomics and personalize medicine through its innovative sequencing technology.
The company's flagship product is the PacBio Sequel System, which is a high-throughput DNA sequencing instrument that uses Single Molecule, Real-Time (SMRT) technology.
This technology allows for the real-time observation of DNA replication, leading to highly accurate and long-read sequencing results.
The system can detect various types of genomic variations, including non-coding DNA, structural variations, and epigenetic modifications.
PacBio's sequencing technology has numerous applications, including studies of genetic diseases, cancer research, microbiome analysis, and forensic analysis.
The company has collaborations with major academic institutions and research centers worldwide, such as the Wellcome Trust Sanger Institute, the Broad Institute, and the Max Planck Institute.
In 2020, PacBio merged with a special purpose acquisition company (SPAC) called Schr'dinger to go public.
The combined company trades on the Nasdaq under a new ticker symbol, "PACB.
" In summary, Pacific Biosciences Of California Inc is a biotech firm known for inventing and producing advanced DNA sequencing technology that allows for highly accurate and long-read sequencing results used for study of genetic diseases, cancer research, microbiome analysis and forensic analysis.
The company has collaborations with major academic institutions worldwide and went public in 2020 in collaboration with Schr'dinger through SPAC.


   Company Address: 1305 O?Brien Drive Menlo Park 94025 CA
   Company Phone Number: 521-8000   Stock Exchange / Ticker: NASDAQ PACB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pacific Biosciences Of California Inc

Pacific Biosciences Of California Inc's Remarkable Revenue Growth Raises Concerns About Operational Efficiency

As a Wall Street journalist, it is important to analyze and dissect the financial performance of companies to provide investors with valuable insights. In the case of Pacific Biosciences Of California Inc, the recent announcement of very solid revenue growth of 113.622% year on year to $58.43 million in the October to December 31, 2023 three months is indeed impressive. However, it is concerning to note that the company reported a net loss of $-0.28 per share during this period.
Despite the strong revenue growth, Pacific Biosciences Of California Inc's behavior is surprising, especially when compared to the rest of the Laboratory Analytical Instruments industry, which experienced a decline in revenue by -4.40%. This raises questions about the company's operational efficiency and profitability.

Pacific Biosciences Of California Inc

Lab Analytical Instruments Company Achieves Remarkable Redemption of Deficit in Q3 2023



Pacific Biosciences Of California Inc, a leading Laboratory Analytical Instruments company, has recently released its financial report for the third quarter ending September 30, 2023. The report highlights a respectable revenue elevation of 69.917% to $54.90 million, supported by measures to cut losses to $-0.26 per share. This represents a significant improvement from the corresponding quarter a year before. The company's performance stands in stark contrast to its peers in the Laboratory Analytical Instruments sector, who have been experiencing business reduction.
Revenue Advancement and Improved EPS:
Pacific Biosciences Of California Inc outperformed its Laboratory Analytical Instruments sector peers by reporting revenue advancement, showcasing the company's ability to withstand the sector's negative momentum. In comparison to the previous quarter, Q3 revenue increased by 15.471% from $47.55 million. Additionally, the company's EPS improved from $-0.28 per share in Q2 to $-0.26 per share in Q3.

Pacific Biosciences Of California Inc

Pacific Biosciences of California Inc Reports Surprising Q2 2023 Performance, Exhibits Promising Growth Trend



The stock market is always abuzz with the latest financial reports and updates from companies, and Pacific Biosciences Of California Inc has recently made some significant strides in the second quarter of 2023. With a decrease in loss per share, improved earnings per share, and substantial revenue growth, the company has showcased its potential for success. This article will delve into the interesting facts and insights from Pacific Biosciences Of California Inc's Q2 2023 financial report.
Decrease in loss per share:
In the second quarter of 2023, Pacific Biosciences Of California Inc demonstrated a promising decrease in its loss per share, reporting $-0.28. This shows a notable improvement from the previous year's $-0.32 loss per share, indicating that the company is making strides towards profitability.

Pacific Biosciences Of California Inc

Pacific Biosciences of California Inc. Reports Strong Revenue Growth in Q1 2023, Yet Challenges Persist in Achieving Profitability

Pacific Biosciences Of California Inc, a biotechnology company that specializes in DNA sequencing technology, reported its financial results for the first quarter of 2023. While the company experienced a loss of $-0.36 per share, this is an improvement from the previous year's loss of $-0.37 per share and the same as the previous financial reporting period.
Despite the loss in earnings per share, the company's revenue grew by a significant 17.264%, reaching $38.90 million, up from $33.17 million in the same financial reporting period a year ago. Sequentially, the company's revenue surged by an impressive 42.215%, reaching $27.35 million. This growth in revenue was driven by an increase in demand for the company's DNA sequencing products and services.
However, the company did experience a net loss of $88.015 million, larger than the $81.499 million loss reported the previous year. This could be attributed to increased research and development costs as the company is constantly striving to develop new and advanced technologies to meet the needs of its clients.






 

Pacific Biosciences Of California Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Pacific Biosciences Of California Inc does not provide revenue guidance.

Earnings Outlook
Pacific Biosciences Of California Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com